Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Cynthia Rudin, PhD, is a highly regarded computer scientist who’s been eyeing the advance of artificial intelligence into society with equal parts enthusiasm and concern.
By now it’s a difficult-to-dispute likelihood: AI won’t replace doctors making diagnoses, but doctors who use AI will displace doctors who don’t use AI. The hypothesis gets a fresh airing out from the vantage point of the general public.
A study published in Human Vaccines & Immunotherapeutics describes researchers' proposal for an alternative flu vaccine that could protect more people and reduce healthcare costs.
3D printing, capable of producing heart models, concreate buildings and prosthetics, is still rapidly advancing. Researchers have developed 3D-printing technology capable of creating human-like skin.
As a way to combat infections after cesarean deliveries, the Society for Maternal-Fetal Medicine conducted a study comparing the effectiveness of poliglecaprone 25 (Monocryl) and polyglactin 910 (Vicryl) in incision closure and rates of wound complications.
A study, published in The Journal of Infectious Diseases, found evidence of the early stages of Ebola and Middle East Respiratory Syndrome (MERS) outbreaks through social media.
The ability to reproduce results of published experiments helps prove affectability in future implementation. A major project in measuring the reliability of cancer research has found a lack of reproducibility to be damaging to the advancement of cancer treatments.
A study of a new HIV neutralizing antibody, 10-1074, has completed its testing in humans. Led by Florian Klein, of the University Hospital Cologne and German Center for Infection Research, the research is published in Nature Medicine.
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York have completed a phase 3 trial on the effectiveness of a drug on advanced liver cancer.
